Renal function markers and metformin eligibility.

CONCLUSIONS: Metformin is the first line pharmacological agent in type 2 Diabetes Mellitus patients, being associated with significant HbA1c reductions and improvements in both micro and macrovascular outcomes. Avoiding its use due to imprecise renal function markers would potentially render the patient deprived of optimal pharmacological therapy for T2D. Creatinine contraindication criteria alone are associated with unnecessary underprescription of metformin. PMID: 28565889 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28565889?dopt=Abstract

Source: Minerva Endocrinologica - June 3, 2017 Category: Endocrinology Tags: Minerva Endocrinol Source Type: research